Tamarae A. Dobbs , FNP-C
Nurse Practitioner • Gainesville, TX
834 W Highway 82 Ste 102
Gainesville, TX 762402533
This profile restates public CMS/NPPES data; T-MedInfo gives no medical advice — consult a licensed professional, and call 911 for emergencies.
-
NPI assigned on April 8, 2008; this date does not establish years in practice.
-
Published CMS data list 24,236 Original Medicare Part B services in 2024.
Source: CMS, Medicare Physician & Other Practitioners – by Provider and Service, 2024. Published rows only; this is not a quality measure.
-
Published Part B service records, 2024:
- J7345 — Aminolevulinic acid hcl for topical administration, 10% gel, 10 mg: 20,400 service units.
- 17003 — Destruction of precancer skin growth, 2-14 growths: 958 service units.
- 99213 — Established patient outpatient office visit: 876 service units.
Source: CMS, Medicare Physician & Other Practitioners – by Provider and Service, 2024. Units differ by code; these are not visits or a measure of quality.
CPT® only copyright 2023 American Medical Association. All rights reserved. Service names are shortened from CPT Consumer Friendly Descriptors (CMS data, 2024). CPT notice
See all 17 records in the table · Guide: How to read Medicare Part B data
-
Published CMS data list 840 Medicare Part D prescriptions, including refills, in 2024.
Source: CMS, Medicare Part D Prescribers – by Provider and Drug, 2024. Published rows only; this is not a quality measure.
-
Published Part D records, 2024:
- Clobetasol Propionate — 130 prescription fills, including refills.
- Mupirocin — 128 prescription fills, including refills.
- Fluorouracil — 108 prescription fills, including refills.
Source: CMS, Medicare Part D Prescribers – by Provider and Drug, 2024. Drug names come from pharmacy claims. Listing a drug here is not an endorsement or a recommendation.
See all 14 records in the table · Guide: How to read Medicare Part D prescriber data
-
More Medicare Part B services than 95% of clinicians listed under Nurse Practitioner in Texas (2024, 1,852 clinicians with data). Median for this group: 219. Middle half: 83 to 548.
Source: CMS, Medicare Physician & Other Practitioners – by Provider and Service, 2024. Billing and prescribing volume is not a quality rating.
-
Medicare Part B services went from 4,354 in 2020 to 24,236 in 2024.
Source: CMS, Medicare Physician & Other Practitioners – by Provider and Service, 2020–2024.
Practice Location & Contact Primary Location
834 W Highway 82 Ste 102
Gainesville, TX 762402533
CMS Doctors and Clinicians lists 1 group name: Bare Derm Group Inc. See the list
Source: CMS Doctors and Clinicians National Downloadable File, release date unavailable.
Listings do not confirm current availability, employment or a shared ownership network.
Medicare Profile & Education
Source: CMS Doctors and Clinicians National Downloadable File
2008
What Public CMS Data Show
Nurse Practitioner: NPPES taxonomy is a reported classification, not proof of board certification.
Medicare patients
906 people with Original Medicare in 2024
It gives a sense of how many people with Medicare this clinician treated that year.
Source: CMS, Medicare Physician & Other Practitioners – by Provider, 2024.
Medicare-allowed amount
About $256,502 in 2024
The total amount Medicare approved for these services in 2024. It includes what Medicare paid and what patients or their other insurance owed, such as the deductible and coinsurance.
It shows the total cost of this clinician's Original Medicare services under Medicare's fee rules.
What this does not show: Medicare-allowed amount
This is not the clinician's income. Part of it can go to a clinic or group practice, staff, equipment or drugs. It is not the price you will pay.
Source: CMS, Medicare Physician & Other Practitioners – by Provider and Service, 2024.
Paid by Medicare
About $177,631 in 2024
The part of the Medicare-allowed amount that Medicare itself paid in 2024, after patients' deductibles and coinsurance.
The gap between the allowed amount and this number is roughly what patients and their other insurance paid.
What this does not show: Paid by Medicare
This is not the clinician's income and not a measure of quality.
Source: CMS, Medicare Physician & Other Practitioners – by Provider and Service, 2024.
30-day fills
981 standardized 30-day fills in 2024
CMS converts prescriptions to 30-day supplies so they can be compared. A 90-day prescription counts as about three 30-day fills.
What this does not show: 30-day fills
It is not a count of patients and not a measure of quality.
Part D drug cost
$408,268 in 2024
The total cost of these prescriptions in 2024, paid by Medicare drug plans, patients and other payers together.
It shows the total spending on drugs this clinician prescribed, not what any one patient paid.
What this does not show: Part D drug cost
A higher cost often reflects the type of medicines a specialty uses. It is not your out-of-pocket cost and not a measure of quality.
Source: CMS, Medicare Part D Prescribers – by Provider and Drug, 2024.
Open Payments general payments, program year 2025
All general payments: $2,039.81 across 116 records.
By nature of payment
- Food and Beverage: $2,039.81 across 116 records.
Reporting-company totals (3 largest of 15)
- ABBVIE INC.: $348.58 across 16 records.
- Galderma Laboratories, L.P.: $338.39 across 24 records.
- Sanofi and Genzyme US Companies: $281.15 across 13 records.
A reported payment does not necessarily mean the financial relationship is improper and is not a measure of care quality. Clinicians can review and dispute these records.
Source: Calculated by T-MedInfo from CMS Open Payments general-payment records for program year 2025 (published June 30, 2026).
Years since graduation
18 years (graduated 2008)
CMS Doctors and Clinicians data list 2008 as the year this clinician finished professional school.
It tells you roughly how long ago the clinician finished school.
What this does not show: Years since graduation
It is not the number of years in practice, and more years does not mean better care.
Source: CMS Doctors and Clinicians National Downloadable File.
NPI first issued
2008
The year this clinician's National Provider Identifier (NPI) was issued. An NPI is a unique 10-digit ID that US health care providers use for billing.
What this does not show: NPI first issued
NPIs have been issued only since 2005, so this year is not necessarily when the clinician started practicing.
Source: CMS NPPES NPI Registry.
Accepts Medicare assignment
CMS data list this clinician as accepting Medicare assignment. This means agreeing to take the Medicare-approved amount as full payment for covered services.
With Original Medicare, you usually pay only your deductible and coinsurance, and the office sends the claim to Medicare for you.
Medicare assignment applies to Original Medicare. It does not tell you whether the clinician is in a Medicare Advantage plan's network, accepts other insurance, or is taking new patients.
Source: CMS Doctors and Clinicians; Medicare.gov, “Does your provider accept Medicare as full payment?”
No telehealth indicator
CMS shows this indicator only when recent Medicare claims include telehealth services. The clinician may still offer telehealth; ask the office.
Source: CMS, Telehealth Indicator on Medicare Care Compare (fact sheet, January 2023); CMS Doctors and Clinicians.
Enrolled in Medicare (PECOS)
Tamarae Dobbs has a Medicare enrollment record in PECOS, the CMS system clinicians use to enroll so they can bill Medicare or order services for people with Medicare.
It does not show whether the clinician accepts assignment, is in your plan's network, or is taking new patients.
Source: CMS Medicare Fee-For-Service Public Provider Enrollment (PECOS); CMS Order and Referring file.
Can order Medicare-covered services
CMS lists Tamarae Dobbs as eligible to order or refer Medicare Part B clinical laboratory and imaging services, durable medical equipment (DME) and home health services for people with Medicare.
Medicare pays for these items and services only when they are ordered by an eligible clinician.
What this does not show: Can order Medicare-covered services
It does not mean the clinician offers these services directly.
Source: CMS Medicare Fee-For-Service Public Provider Enrollment (PECOS); CMS Order and Referring file.
Compared with the same specialty in Gainesville and Texas
Billing and prescribing volume is not a quality rating.
Medicare Part B services
More Medicare Part B services than 95% of clinicians listed under Nurse Practitioner in Texas (2024, 1,852 clinicians with data). Median for this group: 219. Middle half: 83 to 548.
Too few clinicians listed under Nurse Practitioner in Gainesville have Medicare Part B data for 2024 to compare.
Medicare-allowed amount
A higher Medicare-allowed amount than 95% of clinicians listed under Nurse Practitioner in Texas (2024, 1,852 clinicians with data). Median for this group: $17,068. Middle half: $6,758 to $39,305.
Too few clinicians listed under Nurse Practitioner in Gainesville have Medicare Part B data for 2024 to compare.
Paid by Medicare
A higher Medicare payment amount than 95% of clinicians listed under Nurse Practitioner in Texas (2024, 1,852 clinicians with data). Median for this group: $12,638. Middle half: $4,849 to $28,908.
Too few clinicians listed under Nurse Practitioner in Gainesville have Medicare Part B data for 2024 to compare.
Medicare Part D prescriptions
More Part D prescriptions than 65% of clinicians listed under Nurse Practitioner in Texas (2024, 2,095 clinicians with data). Median for this group: 274. Middle half: 77 to 1,097.
Too few clinicians listed under Nurse Practitioner in Gainesville have Medicare Part D data for 2024 to compare.
Part D drug cost
A higher Part D drug cost than 90% of clinicians listed under Nurse Practitioner in Texas (2024, 2,095 clinicians with data). Median for this group: $12,936. Middle half: $998 to $118,416.
Too few clinicians listed under Nurse Practitioner in Gainesville have Medicare Part D data for 2024 to compare.
9 active clinicians are listed under Nurse Practitioner with a practice address in Gainesville, TX (4,835 in Texas).
Addresses are self-reported to NPPES and may be out of date.
CMS data by year
Changes may reflect reporting, coverage or privacy limits, not changes in care quality.
-
Medicare Part B services
Medicare Part B services increased 457% from 4,354 in 2020 to 24,236 in 2024.
- 2020: 4,354
- 2021: 4,525
- 2022: 4,588
- 2023: 10,864
- 2024: 24,236
-
Medicare-allowed amount
Medicare-allowed amount increased 35% from $190,415 in 2020 to $256,502 in 2024.
- 2020: $190,415
- 2021: $219,210
- 2022: $225,320
- 2023: $180,802
- 2024: $256,502
-
Paid by Medicare
Paid by Medicare increased 38% from $128,279 in 2020 to $177,631 in 2024.
- 2020: $128,279
- 2021: $146,849
- 2022: $147,834
- 2023: $115,678
- 2024: $177,631
-
Medicare Part D prescriptions
Medicare Part D prescriptions increased 38% from 608 in 2020 to 840 in 2024.
- 2020: 608
- 2021: 678
- 2022: 786
- 2023: 684
- 2024: 840
-
30-day fills
30-day fills increased 55% from 632 in 2020 to 981 in 2024.
- 2020: 632
- 2021: 735
- 2022: 876
- 2023: 818
- 2024: 981
-
Part D drug cost
Part D drug cost increased 192% from $139,700 in 2020 to $408,268 in 2024.
- 2020: $139,700
- 2021: $338,661
- 2022: $252,134
- 2023: $472,676
- 2024: $408,268
-
Industry payments (Open Payments)
Industry payments (Open Payments) went from $944.04 in 2021 to $2,039.81 in 2025.
- 2021: $944.04
- 2022: $1,260.18
- 2023: $1,658.42
- 2024: $2,405.47
- 2025: $2,039.81
Sources: CMS Medicare Physician & Other Practitioners (2024), CMS Medicare Part D Prescribers (2024), CMS Open Payments (2025), CMS Doctors and Clinicians, CMS NPPES NPI Registry. Specialty names follow the NUCC Health Care Provider Taxonomy.
Text: T-MedInfo · Report an error.
Pharma & Medical Device Financial Disclosures
Payments and other transfers of value that drug and medical device companies reported to CMS Open Payments
Program year 2025 (payments made January 1 – December 31, 2025): 116 records totaling $2,039.81.
| Manufacturer | Payment Nature | Product | Type | Amount ($) |
|---|---|---|---|---|
| Galderma Laboratories, L.P. |
Food and Beverage
In-kind items and services
|
NEMLUVIO | General | $150.00 |
| ABBVIE INC. |
Food and Beverage
In-kind items and services
|
SKYRIZI | General | $112.22 |
| Sanofi and Genzyme US Companies |
Food and Beverage
In-kind items and services
|
DUPIXENT | General | $85.21 |
| SUN PHARMACEUTICAL INDUSTRIES INC. |
Food and Beverage
In-kind items and services
|
ILUMYA | General | $41.67 |
| Regeneron Pharmaceuticals, Inc. |
Food and Beverage
In-kind items and services
|
LIBTAYO | General | $29.70 |
| Sanofi and Genzyme US Companies |
Food and Beverage
In-kind items and services
|
DUPIXENT | General | $28.93 |
| Regeneron Pharmaceuticals, Inc. |
Food and Beverage
In-kind items and services
|
LIBTAYO | General | $28.88 |
| SUN PHARMACEUTICAL INDUSTRIES INC. |
Food and Beverage
In-kind items and services
|
ILUMYA | General | $28.38 |
| Novartis Pharmaceuticals Corporation |
Food and Beverage
In-kind items and services
|
— | General | $26.95 |
| Regeneron Pharmaceuticals, Inc. |
Food and Beverage
In-kind items and services
|
DUPIXENT | General | $26.51 |
| ABBVIE INC. |
Food and Beverage
In-kind items and services
|
RINVOQ | General | $24.58 |
| Amgen Inc. |
Food and Beverage
In-kind items and services
|
OTEZLA | General | $24.42 |
| SUN PHARMACEUTICAL INDUSTRIES INC. |
Food and Beverage
In-kind items and services
|
ILUMYA | General | $24.32 |
| ABBVIE INC. |
Food and Beverage
In-kind items and services
|
SKYRIZI | General | $24.10 |
| Sanofi and Genzyme US Companies |
Food and Beverage
In-kind items and services
|
DUPIXENT | General | $24.00 |
| ABBVIE INC. |
Food and Beverage
In-kind items and services
|
RINVOQ | General | $23.65 |
| Arcutis Biotherapeutics, Inc. |
Food and Beverage
In-kind items and services
|
Zoryve | General | $23.61 |
| Novartis Pharmaceuticals Corporation |
Food and Beverage
In-kind items and services
|
— | General | $23.57 |
| ABBVIE INC. |
Food and Beverage
In-kind items and services
|
SKYRIZI | General | $23.55 |
| SpringWorks Therapeutics, Inc. |
Food and Beverage
In-kind items and services
|
GOMEKLI | General | $23.42 |
| LEO Pharma Inc. |
Food and Beverage
In-kind items and services
|
ADBRY | General | $23.17 |
| Sanofi and Genzyme US Companies |
Food and Beverage
In-kind items and services
|
DUPIXENT | General | $23.00 |
| ABBVIE INC. |
Food and Beverage
In-kind items and services
|
RINVOQ | General | $22.99 |
| ABBVIE INC. |
Food and Beverage
In-kind items and services
|
SKYRIZI | General | $22.71 |
| ABBVIE INC. |
Food and Beverage
In-kind items and services
|
SKYRIZI | General | $22.43 |
(top 25 shown)
Source: CMS Open Payments, program year 2025, released June 30, 2026.
Performed Procedures & Service Volume
CPT® is a registered trademark of the American Medical Association. CPT codes, descriptions and other data only are copyright 2016–2023 American Medical Association. All rights reserved. Applicable FARS/HHSARS apply. Descriptions of CPT codes are the AMA's CPT Consumer Friendly Descriptors as published by CMS in the Medicare Physician & Other Practitioners – by Provider and Service data, 2017–2024; they are plain-language summaries, not for clinical coding or documentation. HCPCS Level II codes and descriptions are from CMS. Fee schedules, relative value units, conversion factors and/or related components are not assigned by the AMA, are not part of CPT, and the AMA is not recommending their use. The AMA does not directly or indirectly practice medicine or dispense medical services. The AMA assumes no liability for data contained or not contained herein.
| HCPCS Code | Services | Patients | Submitted Charge | Medicare Allowed |
|---|---|---|---|---|
|
J7345
Aminolevulinic acid hcl for topical administration, 10% gel, 10 mg
|
20,400 | 51 | $4.63 | $1.66 |
|
17003
Destruction of precancer skin growth, 2-14 growths
|
958 | 227 | $12.67 | $5.27 |
|
99213
Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more
|
876 | 590 | $175.84 | $73.00 |
|
17000
Destruction of precancer skin growth, 1 growth
|
522 | 373 | $130.04 | $44.30 |
|
17110
Destruction of skin growth, 1-14 growths
|
302 | 252 | $217.65 | $90.07 |
|
11102
Biopsy of related skin growth, first growth
|
286 | 245 | $191.77 | $73.30 |
|
99203
New patient office or other outpatient visit with low level of medical decision making, if using time, 30 minutes or more
|
238 | 238 | $215.74 | $89.80 |
|
99214
Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more
|
148 | 109 | $248.98 | $103.22 |
|
99212
Established patient office or other outpatient visit with straightforward medical decision making, if using time, 10 minutes or more
|
114 | 102 | $109.10 | $45.31 |
|
96574
Application of light with debridement to destroy precancer skin growth
|
100 | 50 | $787.34 | $218.16 |
|
96372
Injection of drug or substance under skin or into muscle
|
80 | 27 | $27.57 | $11.45 |
|
11103
Biopsy of related skin growth, each additional growth
|
60 | 44 | $96.12 | $39.88 |
|
99204
New patient office or other outpatient visit with moderate level of medical decision making, if using time, 45 minutes or more
|
42 | 42 | $324.78 | $134.80 |
|
99202
New patient office or other outpatient visit with straightforward medical decision making, if using time, 15 minutes or more
|
37 | 37 | $137.93 | $58.34 |
|
17262
Destruction of cancer skin growth of trunk, arms, or legs, 1.1-2.0 cm
|
32 | 31 | $342.74 | $139.88 |
|
69100
Biopsy of ear
|
23 | 22 | $182.94 | $57.78 |
|
11104
Punch biopsy, first skin growth
|
18 | 18 | $239.30 | $99.29 |
Source: CMS Part B by Provider and Service, 2024; services under 11 beneficiaries omitted by CMS. Privacy limits
Submitted charges are billed amounts, not a price quote for your visit.
Medicare Part D Prescribing Profile & Medications
Medicare Part D prescriptions filled, including refills, in 2024.
| Brand Name | Generic Name | Prescriptions | Day Supply | Total Cost | Patients |
|---|---|---|---|---|---|
| Clobetasol Propionate | Clobetasol Propionate | 130 | 3,594 | $4,350.35 | 92 |
| Mupirocin | Mupirocin | 128 | 3,071 | $949.22 | 107 |
| Fluorouracil | Fluorouracil | 108 | 3,342 | $6,905.53 | 100 |
| Ketoconazole | Ketoconazole | 98 | 2,648 | $1,643.40 | 69 |
| Doxycycline Hyclate | Doxycycline Hyclate | 83 | 2,333 | $1,285.03 | 49 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 81 | 3,145 | $886.93 | 73 |
| Minoxidil | Minoxidil | 57 | 2,990 | $280.70 | 18 |
| Methylprednisolone | Methylprednisolone | 40 | 241 | $227.02 | 32 |
| Clindamycin Phosphate | Clindamycin Phosphate | 27 | 785 | $682.63 | 16 |
| Terbinafine Hcl | Terbinafine Hcl | 22 | 527 | $116.63 | — |
| Valacyclovir | Valacyclovir Hcl | 21 | 595 | $331.02 | 13 |
| Taltz Autoinjector | Ixekizumab | 18 | 504 | $117,472.56 | — |
| Dupixent Pen | Dupilumab | 16 | 448 | $57,800.58 | — |
| Skyrizi Pen | Risankizumab-Rzaa | 11 | 868 | $215,335.90 | — |
Source: CMS Part D by Provider and Drug, 2024; rows below 11 claims omitted by CMS; volume isn’t quality. Privacy limits
Specialties & License Numbers Reported to NPPES
Self-certified to NPPES: 2023-08-31NUCC Taxonomy Code: 363L00000X
(1) A registered nurse provider with a graduate degree in nursing prepared for advanced practice involving independent and interdependent decision making and direct accountability for clinical judgment across the health care continuum or in a certified specialty. (2) A registered nurse who has completed additional training beyond basic nursing education and who provides primary health care services in accordance with state nurse practice laws or statutes. Tasks performed by nurse practitioners vary with practice requirements mandated by geographic, political, economic, and social factors. Nurse practitioner specialists include, but are not limited to, family nurse practitioners, gerontological nurse practitioners, pediatric nurse practitioners, obstetric-gynecologic nurse practitioners, and school nurse practitioners.
Additional State Medicaid & Healthcare Payer Identifiers
Medicare (PECOS) Enrollment & Ordering Eligibility
Source: CMS PECOSPRACTITIONER - NURSE PRACTITIONER
I20110331000424
TX
8123187077
Sources: CMS Provider Enrollment and Order and Referring. Medicare enrollment is a billing status, not an accreditation or quality rating.
Medicare Group Practice Enrollments
Source: CMS Doctors and Clinicians National Downloadable File
Bare Derm Group Inc
834 W Hwy 82, Gainesville, TX 762402533
Phone: 9402947302
Career & Practice History Timeline
Changes recorded in monthly NPPES data files: addresses, names, credentials, specialties and NPI status
Registered at 834 W HIGHWAY 82 STE 102, GAINESVILLE, TX 762402533 (Tel: 9402947302)
Registered at 834 W HIGHWAY 82 STE 102, GAINESVILLE, TX 762402533 (Tel: 9402947302)
Nurse Practitioner (license number reported to NPPES: TX 693151)
NPI status registered as active in NPPES database
Registered at 214 E CALIFORNIA ST, GAINESVILLE, TX 762404004 (Tel: 9723909002)
Registered at 1790 N STONEBRIDGE DR, MCKINNEY, TX 750717437 (Tel: 9723909002)
Recorded as TAMARAE DOBBS, FNP-C
Nurse Practitioner (license number reported to NPPES: TX 693151)
First registered as active Individual Practitioner in NPPES Database.
NPI Administrative Meta
Other Nurse Practitioners in Gainesville
Mailing Address
834 W Highway 82 Ste 102
Gainesville, TX 762402533
Phone: 9402947302